Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radioactive drug targets thyroid tumors in early trial

NCT ID NCT07438847

Recruiting now Disease control Sponsor: SHAOYAN LIU Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new radioactive drug called 177Lu-CTR-FAPI in 12 people with thyroid cancer that has spread and is no longer responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or lower cancer markers in the blood. It is an experimental treatment, not a cure, and aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••